Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases
X Yu, J Sheng, G Pan, Y Fan - International Journal of Cancer, 2021 - Wiley Online Library
Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
[HTML][HTML] Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant …
Q Zhu, Y Sun, Y Cui, K Ye, C Yang, D Yang, J Ma… - Oncotarget, 2017 - ncbi.nlm.nih.gov
This study compared treatment outcomes between TKI monotherapy and TKI administration
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …
Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
C Ma, J Zhang, D Tang, X Ye, J Li, N Mu, Z Li… - Frontiers in …, 2020 - frontiersin.org
Background: The significance of uncommon epidermal growth factor receptor (EGFR)
mutations in patients with non-small cell lung cancer (NSCLC) and brain metastasis (BM) …
mutations in patients with non-small cell lung cancer (NSCLC) and brain metastasis (BM) …
Prognostic factors analysis in EGFR mutation‑positive non‑small cell lung cancer with brain metastases treated with whole brain‑radiotherapy and EGFR‑tyrosine …
H Wei, M Su, R Lin, H Li, C Zou - Oncology Letters, 2016 - spandidos-publications.com
The survival time of non‑small cell lung cancer (NSCLC) patients with brain metastases has
been previously reported to be 6.5‑10.0 months, even with systematic treatment. Patients …
been previously reported to be 6.5‑10.0 months, even with systematic treatment. Patients …
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
L Zhao, X Cai, D Chen, X Ye, M Gao, L Lu, H Su… - Radiation …, 2020 - Springer
Background The development of epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs) has dramatically improved the prognosis of patients with EGFR-mutant non …
(EGFR-TKIs) has dramatically improved the prognosis of patients with EGFR-mutant non …
[HTML][HTML] EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases
T Jiang, C Su, X Li, C Zhao, F Zhou, S Ren… - Journal of Thoracic …, 2016 - Elsevier
Introduction Whether EGFR tyrosine kinase inhibitors (TKIs) plus whole brain radiation
therapy (WBRT) provide a better survival benefit than EGFR TKIs alone remains …
therapy (WBRT) provide a better survival benefit than EGFR TKIs alone remains …
Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain …
Y Chen, J Wei, J Cai, A Liu - BMC cancer, 2019 - Springer
Background The treatment strategy for brain metastasis (BM) in patients with epidermal
growth factor receptor (EGFR)-mutant lung adenocarcinoma (LAC) remains controversial. In …
growth factor receptor (EGFR)-mutant lung adenocarcinoma (LAC) remains controversial. In …
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
A Sekine, H Satoh - Medical Oncology, 2017 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non‐small cell lung cancer
MS Ahluwalia, K Becker, BP Levy - The Oncologist, 2018 - academic.oup.com
Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
AF Eichler, KT Kahle, DL Wang, VA Joshi… - Neuro …, 2010 - academic.oup.com
A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …